Increasing feasibility and utility of 18 F-FDOPA PET for the management of glioma
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (10) , 788-795
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council of Australia (631567, APP1045984)
- Cancer Council Queensland
This publication has 88 references indexed in Scilit:
- Voxel-based analysis of 201Tl SPECT for grading and diagnostic accuracy of gliomas: comparison with ROI analysisAnnals of Nuclear Medicine, 2013
- Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survivalNeuro-Oncology, 2012
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Management of Low-Grade GliomaCurrent Neurology and Neuroscience Reports, 2010
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiformeBMC Cancer, 2009
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo ClinicNeuro-Oncology, 2009
- Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastomaNeuro-Oncology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007